Samuel Su Featured in Exclusive PharmaBoardroom Interview
Samuel Su, Founder and CEO of Bestat Pharmaservices Corp., was recently featured in an exclusive interview with PharmaBoardroom, a premier international media platform for the pharmaceutical industry. During the interview, Samuel shared his insights on emerging trends within the Asian biopharmaceutical sector, as well as Bestat's strategic positioning and future vision within the global clinical trial landscape.
In the interview, Samuel highlighted that Asia is rapidly evolving from a "cost-driven clinical trial destination" into a pivotal engine for global drug development. As biotech and pharmaceutical companies from the U.S., Europe, and Japan increasingly launch multi-regional clinical trials in Asia, the regional demand for high-quality CRO partners has seen a significant rise.
"Bestat's role extends beyond being a service provider; we are committed to being the essential bridge connecting Asian innovation with global drug development," Samuel stated. By continuously strengthening clinical execution capabilities and regulatory expertise, Bestat aims to help international clients seamlessly advance cross-regional R&D projects while ensuring that Asian innovations reach the global market more effectively.
Furthermore, Samuel detailed Bestat's core growth strategies, including the acquisition of Trifecta MedTek to establish Taiwan's first integrated "preclinical-to-clinical" one-stop service platform. Positioned as a "Boutique CRO," Bestat focuses on maintaining high-level flexibility and premium service quality while deepening long-term collaborative relationships with clients.
Amidst the rapidly shifting global biotech environment, Samuel emphasized that the coming decade will be a critical period for the sustained growth of Asia's biomedical industry. Bestat will continue to expand its international footprint, enhance partnerships with global clients, and actively participate in the advancement of multi-regional trials to accelerate the market entry of innovative therapies.
This interview also aligns with the United Nations Sustainable Development Goals (SDGs), specifically SDG 3: Good Health and Well-being—by supporting new drug development and clinical research to improve global healthcare quality; and SDG 17: Partnerships for the Goals—by fostering international collaboration and industrial connectivity to drive the sustainable development of the biopharmaceutical sector.
Bestat Pharmaservices remains dedicated to its core values of professionalism, quality, and efficiency. By deepening its international presence and working alongside global partners, the company continues to bring more innovation and possibilities to human health worldwide.
Read the full interview here: https://pharmaboardroom.com/interviews/samuel-su-ceo-and-founder-bestat-pharmaservices/
Samuel Su, Founder and CEO of Bestat Pharmaservices Corp., was recently featured in an exclusive interview with PharmaBoardroom, a premier international media platform for the pharmaceutical industry. During the interview, Samuel shared his insights on emerging trends within the Asian biopharmaceutical sector, as well as Bestat's strategic positioning and future vision within the global clinical trial landscape.
In the interview, Samuel highlighted that Asia is rapidly evolving from a "cost-driven clinical trial destination" into a pivotal engine for global drug development. As biotech and pharmaceutical companies from the U.S., Europe, and Japan increasingly launch multi-regional clinical trials in Asia, the regional demand for high-quality CRO partners has seen a significant rise.
"Bestat's role extends beyond being a service provider; we are committed to being the essential bridge connecting Asian innovation with global drug development," Samuel stated. By continuously strengthening clinical execution capabilities and regulatory expertise, Bestat aims to help international clients seamlessly advance cross-regional R&D projects while ensuring that Asian innovations reach the global market more effectively.
Furthermore, Samuel detailed Bestat's core growth strategies, including the acquisition of Trifecta MedTek to establish Taiwan's first integrated "preclinical-to-clinical" one-stop service platform. Positioned as a "Boutique CRO," Bestat focuses on maintaining high-level flexibility and premium service quality while deepening long-term collaborative relationships with clients.
Amidst the rapidly shifting global biotech environment, Samuel emphasized that the coming decade will be a critical period for the sustained growth of Asia's biomedical industry. Bestat will continue to expand its international footprint, enhance partnerships with global clients, and actively participate in the advancement of multi-regional trials to accelerate the market entry of innovative therapies.
This interview also aligns with the United Nations Sustainable Development Goals (SDGs), specifically SDG 3: Good Health and Well-being—by supporting new drug development and clinical research to improve global healthcare quality; and SDG 17: Partnerships for the Goals—by fostering international collaboration and industrial connectivity to drive the sustainable development of the biopharmaceutical sector.
Bestat Pharmaservices remains dedicated to its core values of professionalism, quality, and efficiency. By deepening its international presence and working alongside global partners, the company continues to bring more innovation and possibilities to human health worldwide.
Read the full interview here: https://pharmaboardroom.com/interviews/samuel-su-ceo-and-founder-bestat-pharmaservices/